TTR and Alzheimer disease: Although there are currently no data on changes in endogenous CTS levels in the brains of AD patients, it is plausible that the decrease in plasma marinobufagenin in AD may result from impaired hippocampal function (Qi et al., 2024), as the hippocampus is a source of CTS in the brain.